In summary, results from these experiments reports a novel mechanistic role of DVL2 and HER2 depletion in modulating EGFR signaling activation in HER2+ breast cancer, which in turn, opens a new area of investigation of how Wnt and EGFR crosstalk might affect HER2+ breast cancer progression in the clinical setting. This evidence concerns the gene EGFR and breast carcinoma.